Drugs for Single Ventricular Heart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 73)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Ambrisentan |
Approved, Investigational |
Phase 4 |
|
177036-94-1 |
6918493 |
|
Synonyms:
(2S)-2-[(4,6-DIMETHYLPYRIMIDIN-2-YL)OXY]-3-METHOXY- 3,3-DIPHENYLPROPANOIC ACID
AMBRISENTAN
GSK1325760
GSK-1325760
GSK1325760A
|
GSK-1325760A
LETAIRIS
Letairis®
LU-208075
VOLIBRIS
|
|
| 2 |
|
Sildenafil |
Approved, Investigational |
Phase 4 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
|
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
| 3 |
|
Carvedilol |
Approved, Investigational |
Phase 4 |
|
72956-09-3 |
2585 |
|
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
14C-Labeled carvedilol
Artist
BM 14.190
BM-14.190
BM-14190
BM-14-190
C07AG02
CARVEDILOL
Carvédilol
Carvedilol hydrochloride
Carvedilol, (-)
Carvedilol, (-)-isomer
Carvedilol, (+)
Carvedilol, (+)-isomer
Carvedilol, (+-)-isomer
Carvedilol, (R)-isomer
Carvedilol, (S)-isomer
Carvedilol, 14C labeled
|
Carvedilol, 14C-labeled
Carvedilolum
Carvedilolum [Latin]
Coreg
COREG CR
Coreg®|DQ 2466|Eucardic®|SKF 105517
Coropres
Dilatrend
DQ 2466
DQ-2466
Eucardic
EUCARDIC 12.5
EUCARDIC 25
EUCARDIC 3.125
EUCARDIC 6.25
Kredex
Querto
SKF 105517
SKF-105517
|
|
| 4 |
|
Dobutamine |
Approved |
Phase 4 |
|
34368-04-2 |
36811 |
|
Synonyms:
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-b-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
Boehringer ingelheim brand OF dobutamine hydrochloride
COMPOUND 81929
COMPOUND-81929
DL-Dobutamine
Dobucor
Dobuject
Dobutamin
Dobutamin fresenius
Dobutamin hexal
Dobutamin ratiopharm
Dobutamin solvay
Dobutamina
Dobutamina [INN-Spanish]
Dobutamina inibsa
Dobutamina rovi
Dobutamine
Dobutamine (+)-isomer
Dobutamine [Usan:Ban:Inn]
Dobutamine [Usan]
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine hydrobromide
Dobutamine hydrochloride
dobutamine hydrochloride|Dobutrex®|Inotrex®
Dobutamine lactobionate
Dobutamine phosphate (1:1) salt, (-)-isomer
|
Dobutamine tartrate
Dobutamine tartrate (1:1), (R-(r*,r*))-isomer
Dobutamine tartrate (1:1), (S-(r*,r*))-isomer
Dobutamine, (-)-isomer
Dobutamine, phosphate (1:1) salt (+)-isomer
Dobutamin-ratiopharm
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
Eli lilly brand OF dobutamine hydrochloride
Fresenius brand OF dobutamine hydrochloride
Hexal brand OF dobutamine hydrochloride
Hydrobromide, dobutamine
Hydrochloride, dobutamine
Inibsa brand OF dobutamine hydrochloride
Inotrex
Irisfarma brand OF dobutamine hydrochloride
Juste brand OF dobutamine hydrochloride
Kendrick brand OF dobutamine hydrochloride
Lactobionate, dobutamine
Lilly 81929
Lilly brand OF dobutamine hydrochloride
Oxiken
Pisa brand OF dobutamine hydrochloride
Posiject
rac-Dobutamine
Racemic-dobutamine
Ratiopharm brand OF dobutamine hydrochloride
Rovi brand OF dobutamine hydrochloride
Solvay brand OF dobutamine hydrochloride
Tartrate, dobutamine
|
|
| 5 |
|
Eplerenone |
Approved |
Phase 4 |
|
107724-20-9 |
443872 |
|
Synonyms:
9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone
Eplerenon
Eplerenona
EPLERENONE
Epoxymexrenone
|
Inspra
Inspra®|SC-66110
SC-66110
SC-6611O
|
|
| 6 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
| 7 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
| 8 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
| 9 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
| 10 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
| 11 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
| 12 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
| 13 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
| 14 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
| 15 |
|
Antioxidants |
|
Phase 4 |
|
|
|
| 16 |
|
Protective Agents |
|
Phase 4 |
|
|
|
| 17 |
|
Hormones |
|
Phase 4 |
|
|
|
| 18 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
| 19 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
| 20 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
| 21 |
|
diuretics |
|
Phase 4 |
|
|
|
| 22 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
| 23 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
| 24 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
|
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
| 25 |
|
Udenafil |
Approved, Investigational |
Phase 3 |
|
268203-93-6 |
6918523 135413547 |
|
Synonyms:
3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-N-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxybenzenesulfonamide
DA-8159
DA-8159|DA8159|Zydena®
|
DA-8159udenafil
UDENAFIL
Zidena
|
|
| 26 |
|
Enalaprilat |
Approved |
Phase 3 |
|
76420-72-9 |
6917719 5462501 |
|
Synonyms:
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
Anhydrous enalaprilat citrate
Anhydrous, enalaprilat
Biovail brand OF enalaprilat anhydrous
Boehringer ingelheim brand OF enalaprilat anhydrous
Dihydrate, enalaprilat
Enalapril acid
Enalapril diacid
Enalapril teva
ENALAPRILAT
Enalaprilat anhydrous
Enalaprilat citrate, anhydrous
Enalaprilat dihydrate
Enalaprilat, (R)-isomer, anhydrous
|
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalapril-teva
EnalaprilTEVA
Merck frosst brand OF enalaprilat anhydrous
MK-421
MK-422
MSD Brand OF enalaprilat
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
Pres IV
Teva brand OF enalaprilat
Vasotec
Xanef
|
|
| 27 |
|
Enalapril |
Approved, Vet_approved |
Phase 3 |
|
75847-73-3 |
40466924 5388962 5362032 |
|
Synonyms:
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylate
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Analapril
ánalapril
Bonuten
C09AA02
ENALADEX
Enaladex®|Vasotec®
Enalapril
Enalapril Bp
Enalapril maleate
Enalapril Richet
Enalaprila
|
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
Enalaprilum [INN-Latin]
EPL753
Gadopril
Kinfil
LEXXEL
Maleate, enalapril
Renitec
Renitek
VASERETIC
VASOTEC
Vasotec IV
|
|
| 28 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
| 29 |
|
Colchicine |
Approved |
Phase 2, Phase 3 |
|
64-86-8 |
2833 6167 |
|
Synonyms:
(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
BENZO(A)HEPTALEN-9(5H)-ONE
Colchicin
Colchicina
COLCHICINE
Colchicinum
COLCRYS
Colcrys®|methoxylated analogue of XD1|XD25
COLGOUT
|
COLSALOID
CONDYLON
GLOPERBA
MITIGARE
N-(1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDROBENZO[A]HEPTALEN-7-YL)ACETAMIDE
N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
N-ACETYLTRIMETHYLCOLCHICINIC ACID METHYL ETHER
NSC-757
|
|
| 30 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
|
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
| 31 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 2, Phase 3 |
|
74-79-3 |
6322 |
|
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
| 32 |
|
Angiotensin-Converting Enzyme Inhibitors |
|
Phase 3 |
|
|
|
| 33 |
|
HIV Protease Inhibitors |
|
Phase 3 |
|
|
|
| 34 |
|
protease inhibitors |
|
Phase 3 |
|
|
|
|
Synonyms:
|
| 35 |
|
Phosphodiesterase Inhibitors |
|
Phase 3 |
|
|
|
| 36 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 3 |
|
|
|
| 37 |
|
Citrate |
|
Phase 3 |
|
|
|
| 38 |
|
Arginine Vasopressin |
|
Phase 2, Phase 3 |
|
|
|
| 39 |
|
Vasopressins |
|
Phase 2, Phase 3 |
|
|
|
| 40 |
|
Vasoconstrictor Agents |
|
Phase 2, Phase 3 |
|
|
|
| 41 |
|
Hemostatics |
|
Phase 2, Phase 3 |
|
|
|
| 42 |
|
Coagulants |
|
Phase 2, Phase 3 |
|
|
|
| 43 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
| 44 |
|
Antimitotic Agents |
|
Phase 2, Phase 3 |
|
|
|
| 45 |
|
Tubulin Modulators |
|
Phase 2, Phase 3 |
|
|
|
| 46 |
|
Bosentan |
Approved, Investigational |
Phase 2 |
|
147536-97-8 |
104865 |
|
Synonyms:
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulphornamide
4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
BOSENTAN
BOSENTÁN
Bosentan anhydrous
Bosentan hydrate
Bosentan monohydrate
|
Bosentanum
p-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulphonamide
RO 47-0203
RO 47-0203|Tracleer®
RO-470203029
RO-47-0203-029
Tracleer
|
|
| 47 |
|
Spironolactone |
Approved |
Phase 1, Phase 2 |
|
1952-01-7, 52-01-7 |
5833 |
|
Synonyms:
ABBOLACTONE
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone a
Aldactone®|spiractin|spirotone
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alpharma brand OF spironolactone
Alter brand OF spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Azupharma brand OF spironolactone
Betapharm brand OF spironolactone
Cardel brand OF spironolactone
CAROSPIR
CT Arzneimittel brand OF spironolactone
CT, Spiro von
CT-Arzneimittel brand OF spironolactone
Deverol
Dexo brand OF spironolactone
DIATENSEC
Dira
Duraspiron
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
GX SPIRONOL
Hormosan brand OF spironolactone
Jenapharm brand OF spironolactone
Jenaspiron
Lacalmin
Lacdene
LARACTONE
Mayoly-spindler brand OF spironolactone
Melarcon
Merck dura brand OF spironolactone
Mundogen brand OF spironolactone
Nefurofan
Novo spiroton
Novopharm brand OF spironolactone
Novo-spiroton
NovoSpiroton
NSC-150399
Osyrol
Pfizer brand OF spironolactone
|
Pharmafrid brand OF spironolactone
Practon
Roche brand OF spironolactone
Sagisal
SC-9420
Searle brand OF spironolactone
Sincomen
SNL
Spiractin
Spiresis
SPIRETIC
Spiridon
SPIRNOLACTONE
Spiro l.u.t.
Spiro von CT
Spirobeta
Spiroctan
SPIROCTAN 100
SPIROCTAN 25
SPIROCTAN 50
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono isis
Spironocompren
Spirono-isis
SPIRONOLACTONE
Spironolactone [BAN:INN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
SPIROSPARE 100
SPIROSPARE 25
Spiro-Tablinen
SPIROTONE
Sprioderm
Supra-puren
Suracton
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
Von CT, spiro
Wörwag brand OF spironolactone
Xenalon
|
|
| 48 |
|
Endothelin Receptor Antagonists |
|
Phase 2 |
|
|
|
| 49 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2 |
|
|
|
| 50 |
|
Tadalafil |
Approved, Investigational |
Phase 1 |
|
171596-29-5 |
110635 |
|
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
351, IC
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
Adcirca
Adcirca®|Cialis®|IC-351|IC351
Cialis
|
IC351
IC-351
ICOS 351
Tadalafil
Tadalafilo
Tadanafil
Zalutia
|
|
Interventional clinical trials:
(show top 50)
(show all 83)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
The Effects of Ambrisentan on Exercise Capacity in Fontan Patients |
Completed |
NCT01971580 |
Phase 4 |
Ambrisentan |
| 2 |
Effect of Carvedilol on Exercise Performance in Fontan Patients |
Completed |
NCT02946892 |
Phase 4 |
Carvedilol;Placebo |
| 3 |
Response to Sildenafil in Patients With Fontan Physiology, A Pressure-volume Loop Analysis |
Completed |
NCT01815502 |
Phase 4 |
|
| 4 |
Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease |
Terminated |
NCT01971593 |
Phase 4 |
Eplerenone |
| 5 |
A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation |
Unknown status |
NCT03013751 |
Phase 3 |
Udenafil |
| 6 |
The Influence of Postoperative Systemic Oxygen Transport on Neurologic and Functional Outcomes in Infants Undergoing Single Ventricle Palliation With Norwood and Hybrid Management Strategies |
Unknown status |
NCT01134302 |
Phase 3 |
|
| 7 |
Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL) |
Completed |
NCT02741115 |
Phase 3 |
Udenafil;Placebo |
| 8 |
Use of Arginine Vasopressin in Early Postoperative Management After Fontan Palliation |
Completed |
NCT03088345 |
Phase 2, Phase 3 |
Vasopressin, Arginine;Placebo |
| 9 |
Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network) |
Completed |
NCT00115934 |
Phase 3 |
|
| 10 |
Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network) |
Completed |
NCT00113087 |
Phase 3 |
Enalapril;Placebo |
| 11 |
Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study |
Recruiting |
NCT02781922 |
Phase 3 |
|
| 12 |
Phosphodiesterase-type 5 Inhibitors in Adult and Adolescent Patients With Univentricular Heart Disease: a Multi-center, Randomized, Double Blind Phase III Study |
Not yet recruiting |
NCT03997097 |
Phase 3 |
Sildenafil;Placebos |
| 13 |
Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies |
Suspended |
NCT02975999 |
Phase 2, Phase 3 |
Vasopressin;Normal Saline |
| 14 |
Colchicine in Postoperative Fontan Patients (CPFP) |
Terminated |
NCT03575572 |
Phase 2, Phase 3 |
Colchicine |
| 15 |
Bosentan Therapy for High Risk Staged Fontan Procedure in Children With Functional Single Ventricle |
Completed |
NCT01662037 |
Phase 2 |
Bosentan |
| 16 |
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation |
Completed |
NCT02201342 |
Phase 1, Phase 2 |
Udenafil |
| 17 |
Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients |
Completed |
NCT02080637 |
Phase 2 |
Ambrisentan |
| 18 |
Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection. |
Recruiting |
NCT04467671 |
Phase 2 |
|
| 19 |
Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention |
Recruiting |
NCT04901975 |
Phase 1, Phase 2 |
Spironolactone |
| 20 |
Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle |
Active, not recruiting |
NCT03079401 |
Phase 1, Phase 2 |
|
| 21 |
A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery |
Completed |
NCT01034007 |
Phase 1 |
|
| 22 |
Phase I Study of Cardiac Progenitor Cell Therapy in Patients With Single Ventricle Physiology |
Completed |
NCT01273857 |
Phase 1 |
|
| 23 |
Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients |
Completed |
NCT01291069 |
Phase 1 |
Tadalafil Citrate;Sugar pill |
| 24 |
Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure |
Completed |
NCT00004828 |
Phase 1 |
liothyronine I 131 |
| 25 |
Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients |
Completed |
NCT01169519 |
Phase 1 |
Sildenafil by injection |
| 26 |
" An Open Label Pilot Study Evaluating Safety and Evidence of Therapeutic Effect of IV Admin of 2-0, 3-0 Desulfated Heparin, Treatment of Exacerbation of Protein Losing Enteropathy (PLE) Associated With Single Ventricle Palliative Surgery" |
Terminated |
NCT01161641 |
Phase 1 |
ODSH at 0.125 mg/kg/h;ODSH at 0.375 mg/kg/h;ODSH at 0.250 mg/kg/h |
| 27 |
Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation |
Unknown status |
NCT02995577 |
|
|
| 28 |
Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study |
Unknown status |
NCT03430583 |
|
MZ101 |
| 29 |
Long-term Survival After Single-ventricle Palliation: A Swedish Nationwide Cohort Study |
Unknown status |
NCT03356574 |
|
|
| 30 |
Cognitive Intervention to Improve Working Memory in Adolescents With Single Ventricle Heart Disease |
Completed |
NCT03687008 |
|
|
| 31 |
Redesigning the Care Journey of Patients With Single-ventricle Congenital Heart Disease |
Completed |
NCT04613934 |
|
|
| 32 |
Adaptation of Alveolar-capillary Diffusion at Effort of Subjects Suffering From Complex Congenital Heart Disease |
Completed |
NCT02561975 |
|
|
| 33 |
A Magnetic Resonance Imaging Study to Determine Cerebral Blood Flow Changes in Single Ventricle Patients During Staged Reconstruction as Compared to Normal Children |
Completed |
NCT02135081 |
|
|
| 34 |
Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training |
Completed |
NCT01977222 |
|
|
| 35 |
Heart Failure and Fibrosis in Adult Congenital Heart Patients With a Single Ventricle and Prior Fontan Operation. |
Completed |
NCT01929174 |
|
|
| 36 |
Assessment of Exercise Capacity in Single-ventricle Patients Undergoing Fontan Procedure |
Completed |
NCT05063903 |
|
|
| 37 |
Cardiovascular, Pulmonary and Skeletal Muscle Evaluation in Patients With Univentricular Physiology in the Late Postoperative Period of the Fontan Surgery: Effects of Exercise Training |
Completed |
NCT02283255 |
|
|
| 38 |
A Pilot Study of Inspiratory Muscle Function and the Effects of Inspiratory Muscle Training in Subjects With Fontan Physiology |
Completed |
NCT03339466 |
|
|
| 39 |
Training in Exercise Activities and Motion for Growth (A Study Conducted by the Pediatric Heart Network) |
Completed |
NCT01917084 |
|
|
| 40 |
Parents Post-traumatic Stress Before and After Their Infant's Second Palliative Heart Surgery: The PaTHS Descriptive Correlational Longitudinal Study |
Completed |
NCT04785482 |
|
|
| 41 |
The Examination of Outcome in Children With Single Ventricle Physiology |
Completed |
NCT00308217 |
|
|
| 42 |
Cross-sectional Analysis of Non-invasive Measures of Ventricular Systolic and Diastolic Function and Biomarkers in the Fontan Circulation |
Completed |
NCT03119090 |
|
|
| 43 |
Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology Requiring Neonatal Surgery |
Completed |
NCT02462434 |
|
|
| 44 |
Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease |
Completed |
NCT03877965 |
|
Digoxin |
| 45 |
Single Ventricle Reconstruction III: Brain Connectome and Neurodevelopmental Outcomes |
Completed |
NCT02692443 |
|
|
| 46 |
Cardiac Biomarkers in Patients With Single Ventricle Physiology |
Completed |
NCT03678909 |
|
|
| 47 |
Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation |
Completed |
NCT00974025 |
|
|
| 48 |
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy |
Completed |
NCT00165984 |
|
|
| 49 |
Factors Associated With Normal Exercise Capacity in Patients With Single Ventricle: the Multicenter Cross-sectional Study |
Completed |
NCT04026542 |
|
|
| 50 |
Parental Experience in the Single Ventricle Interstage Utilizing a mHealth Innovation: A Comparative Case Study |
Completed |
NCT03231020 |
|
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Single Ventricular Heart:
Embryonic/Adult Cultured Cells Related to Single Ventricular Heart:
|
